Insider transaction details
Disc Medicine (NASDAQ: IRON) Chief Medical Officer William Jacob Savage executed a sale of 3,256 shares of the company’s common stock on February 17, 2026, at a price of $62.86 per share. The total value of the transaction was $204,672. Following the sale, Savage directly holds 92,589 shares of Disc Medicine.
The company disclosed that the sale was carried out to satisfy tax withholding responsibilities connected to the vesting of restricted stock units. No other change to Savage’s ownership beyond the stated post-sale balance was disclosed.
Regulatory development on bitopertin
Separately, Disc Medicine has experienced a significant regulatory development regarding its erythropoietic protoporphyria (EPP) candidate, bitopertin. The U.S. Food and Drug Administration issued a Complete Response Letter requesting further data from the ongoing Phase 3 APOLLO study before it can consider approval.
The FDA’s communication acknowledged that bitopertin produces a meaningful reduction in protoporphyrin IX (PPIX) levels. However, regulators determined that earlier trials did not adequately demonstrate a clear link between reductions in PPIX and clinical endpoints based on sunlight exposure, leading to the request for additional evidence.
Analyst reactions and market posture
Following the FDA action, several sell-side analysts adjusted price targets for Disc Medicine while generally retaining positive recommendation stances. Stifel reduced its price target to $110 from $125 and maintained a Buy rating. Cantor Fitzgerald lowered its target to $125 from $153 while keeping an Overweight rating. BMO Capital reiterated an Outperform rating with a $120 price target and expressed continued optimism about the prospect of eventual approval for bitopertin.
These analyst moves reflect differing assessments of the regulatory pathway but do not, in the cases noted, change the respective firms' overall recommendation levels.
Takeaway
The insider sale by the company’s chief medical officer was explicitly executed to cover tax obligations tied to RSU vesting. At the same time, Disc Medicine faces heightened regulatory scrutiny for its lead EPP therapy, prompting requests for further Phase 3 evidence and producing mixed analyst adjustments to price targets amid maintained positive ratings.
Reporting here is focused on the disclosed transaction and confirmed regulatory and analyst actions; no additional claims or inferences beyond those disclosures are made.